The path from a drug candidate to an approved medicine runs through clinical trials. Each phase has a distinct goal, patient population, and risk profile. Understanding the phases is essential whether you’re a researcher, patient, or industry observer.
Before clinical trials: IND submission
Before testing in humans, sponsors file an Investigational New Drug (IND) application with the FDA (or CTA in Europe). The IND includes preclinical data, manufacturing details, and the proposed clinical protocol. The FDA has 30 days to review and clear the IND.
Phase I: First-in-human
Primary goal: Safety, tolerability, pharmacokinetics, and dose finding.
- Participants: 20–80 healthy volunteers (sometimes patients for cytotoxic drugs)
- Design: Often dose-escalation — starting at a fraction of the maximum tolerated dose in animals, escalating in cohorts
- Duration: Months to a year
- Outcomes: Maximum tolerated dose (MTD), recommended Phase II dose (RP2D), PK parameters, initial safety profile
Phase I trials for oncology drugs use patients (not healthy volunteers) because cytotoxic drugs are too dangerous for healthy people.
Phase II: Efficacy signal and dose
Primary goal: Establish efficacy in the target patient population and refine dose.
- Participants: 100–300 patients with the target disease
- Design: Often randomized against placebo or standard of care; sometimes single-arm with historical controls
- Duration: 1–2 years
- Outcomes: Efficacy signal, optimal dosing regimen, expanded safety profile, biomarker validation
Phase II is where most drugs fail — the efficacy demonstrated in animals or early human studies often doesn’t translate to robust signals in patients.
Phase III: Pivotal trials
Primary goal: Confirm efficacy and safety in a large patient population sufficient for regulatory approval.
- Participants: 1,000–3,000+ patients across multiple sites and countries
- Design: Randomized, controlled, often double-blind; comparison to placebo or active comparator
- Duration: 2–4 years
- Outcomes: Statistically significant clinical benefit, comprehensive safety profile, regulatory submission package
FDA approval typically requires two adequate and well-controlled Phase III trials, though there are exceptions for rare diseases or accelerated approval pathways.
Regulatory submission and approval
If Phase III trials are successful, the sponsor files a New Drug Application (NDA, for small molecules) or Biologics License Application (BLA, for biologics). The FDA review takes 6–12 months. Priority review is granted for drugs with significant clinical advantage and shortens this to 6 months.
Phase IV: Post-marketing surveillance
Primary goal: Long-term safety monitoring and additional indications.
- Participants: Real-world patient populations
- Design: Mandatory post-marketing requirements, observational studies, registries, additional randomized trials
- Duration: Ongoing
- Outcomes: Detection of rare adverse events, drug-drug interactions, label expansions
Special pathways
- Accelerated approval: Based on a surrogate endpoint reasonably likely to predict clinical benefit. Requires confirmatory trials post-approval
- Breakthrough therapy designation: Expedited development for drugs treating serious conditions with substantial improvement over existing therapies
- Orphan drug designation: For rare diseases (<200,000 patients in the US); offers tax credits and market exclusivity
- Fast Track: Increased FDA interaction and rolling review
Trial design considerations
- Randomization: Reduces bias by balancing known and unknown patient characteristics
- Blinding: Single-blind (patient unaware), double-blind (patient and investigator unaware), open-label
- Endpoints: Primary (the main question), secondary (supporting evidence), exploratory
- Statistical power: Sample size calculated to detect a clinically meaningful effect with acceptable false-positive and false-negative rates
- Adaptive designs: Modify the trial based on accumulating data (sample size, treatment arms, dose) under pre-specified rules
Common reasons trials fail
- Lack of efficacy in target population
- Unexpected safety signals
- Insufficient differentiation from existing therapies
- Incorrect patient selection
- Statistical underpowering
- Operational issues (recruitment, site quality)
Clinical trials are rigorous, expensive, and slow because the stakes are high — patient safety and efficacy must be established with confidence before a drug becomes available. Each phase asks a different question, and only drugs that answer all of them favorably reach approval.
